DE60045720D1 - Behandlung von Krebs beim Menschen mit ET743 - Google Patents

Behandlung von Krebs beim Menschen mit ET743

Info

Publication number
DE60045720D1
DE60045720D1 DE60045720T DE60045720T DE60045720D1 DE 60045720 D1 DE60045720 D1 DE 60045720D1 DE 60045720 T DE60045720 T DE 60045720T DE 60045720 T DE60045720 T DE 60045720T DE 60045720 D1 DE60045720 D1 DE 60045720D1
Authority
DE
Germany
Prior art keywords
humans
cancer
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60045720T
Other languages
English (en)
Inventor
Esteban Cvltkovic
George Daniel Demetri
Cecilia Guzman
Jose Jimeno
Lazaro Luis Lopez
Jean Louis Misset
Chris Twelves
Hoff Daniel D Von
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmamar SA
Original Assignee
Pharmamar SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9911183.3A external-priority patent/GB9911183D0/en
Priority claimed from GBGB9911346.6A external-priority patent/GB9911346D0/en
Priority claimed from GBGB9918534.0A external-priority patent/GB9918534D0/en
Priority claimed from GBGB9927005.0A external-priority patent/GB9927005D0/en
Priority claimed from GBGB9927106.6A external-priority patent/GB9927106D0/en
Priority claimed from GB0007637A external-priority patent/GB0007637D0/en
Application filed by Pharmamar SA filed Critical Pharmamar SA
Application granted granted Critical
Publication of DE60045720D1 publication Critical patent/DE60045720D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
DE60045720T 1999-05-13 2000-05-15 Behandlung von Krebs beim Menschen mit ET743 Expired - Lifetime DE60045720D1 (de)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GBGB9911183.3A GB9911183D0 (en) 1999-05-13 1999-05-13 Treatment of cancers
GBGB9911346.6A GB9911346D0 (en) 1999-05-14 1999-05-14 Treatment of cancers
GBGB9918534.0A GB9918534D0 (en) 1999-08-05 1999-08-05 Treatment of cancers
GBGB9927005.0A GB9927005D0 (en) 1999-11-15 1999-11-15 Treatment of cancers
GBGB9927106.6A GB9927106D0 (en) 1999-11-16 1999-11-16 Cancer treatment
GB0007637A GB0007637D0 (en) 2000-03-29 2000-03-29 Antitumour compound

Publications (1)

Publication Number Publication Date
DE60045720D1 true DE60045720D1 (de) 2011-04-21

Family

ID=27546594

Family Applications (4)

Application Number Title Priority Date Filing Date
DE122008000013C Pending DE122008000013I1 (de) 1999-05-13 2000-05-15 Verwendung von et743 in kombinationstherapie mit dexamethason zur behandlung von krebs
DE60030554T Active DE60030554T8 (de) 1999-05-13 2000-05-15 Verwendungen von et743 zur behandlung von krebs
DE60045720T Expired - Lifetime DE60045720D1 (de) 1999-05-13 2000-05-15 Behandlung von Krebs beim Menschen mit ET743
DE60036826T Expired - Lifetime DE60036826T2 (de) 1999-05-13 2000-05-15 Verwendung von et743 in kombinationstherapie mit dexamethason zur behandlung von krebs

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DE122008000013C Pending DE122008000013I1 (de) 1999-05-13 2000-05-15 Verwendung von et743 in kombinationstherapie mit dexamethason zur behandlung von krebs
DE60030554T Active DE60030554T8 (de) 1999-05-13 2000-05-15 Verwendungen von et743 zur behandlung von krebs

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE60036826T Expired - Lifetime DE60036826T2 (de) 1999-05-13 2000-05-15 Verwendung von et743 in kombinationstherapie mit dexamethason zur behandlung von krebs

Country Status (32)

Country Link
US (1) US8119638B2 (de)
EP (3) EP1702618B1 (de)
JP (2) JP2002544231A (de)
KR (1) KR20020019914A (de)
CN (2) CN100477993C (de)
AR (1) AR028476A1 (de)
AT (3) ATE338552T1 (de)
AU (2) AU777417B2 (de)
BG (1) BG65680B1 (de)
BR (1) BR0010531A (de)
CA (1) CA2373794C (de)
CY (4) CY1105818T1 (de)
CZ (1) CZ301482B6 (de)
DE (4) DE122008000013I1 (de)
DK (3) DK1716853T3 (de)
ES (2) ES2294756T3 (de)
FR (1) FR08C0013I2 (de)
HU (2) HU229866B1 (de)
IL (2) IL146434A0 (de)
LU (1) LU91418I2 (de)
MX (1) MXPA01011562A (de)
MY (1) MY164077A (de)
NL (1) NL300337I2 (de)
NO (2) NO324564B1 (de)
NZ (1) NZ515423A (de)
PL (1) PL198185B1 (de)
PT (3) PT1176964E (de)
SI (3) SI1716853T1 (de)
SK (1) SK287580B6 (de)
TR (1) TR200103819T2 (de)
UA (1) UA74782C2 (de)
WO (1) WO2000069441A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164077A (en) 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
CA2428160C (en) * 2000-11-06 2009-10-13 Pharma Mar, S.A. Compositions for antitumor treatment containing ecteinascidin 743
GB0117402D0 (en) * 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
HUP0401903A3 (en) * 2001-10-19 2008-07-28 Pharma Mar Improved use of et-743 in cancer thereapy
GB0202544D0 (en) 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
GB0324201D0 (en) * 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
RS50692B (sr) * 2003-11-13 2010-06-30 Pharma Mar S.A.U. Kombinacija et-743 sa prolekovima 5-fluorouracila za lečenje kancera
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
AU2004291037A1 (en) * 2003-11-14 2005-06-02 Pharma Mar, S.A. Combination therapy comprising the use of ET-743 and paclitaxel for treating cancer
MX2007000360A (es) * 2004-07-09 2007-06-12 Pharma Mar Sa Marcadores moleculares de pronostico.
NZ554765A (en) * 2004-10-26 2010-01-29 Pharma Mar Sa Pegylated Liposomal Doxorubicin In Combination With Ecteinescidin 743
DE602005001833T2 (de) * 2004-10-29 2008-04-17 Pharma Mar S.A., Sociedad Unipersonal Zusammensetzungen enthaltend Ecteinascidin und einen Disaccharide
GB0522082D0 (en) * 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
JP2009536956A (ja) * 2006-05-12 2009-10-22 ファルマ・マール・ソシエダード・アノニマ 抗癌治療法
US20100267732A1 (en) * 2007-10-19 2010-10-21 Pharma Mar, S.A. Prognostic Molecular Markers for ET-743 Treatment
MX2018009088A (es) 2016-02-04 2018-09-03 Jiangsu Hengrui Medicine Co Composicion farmaceutica inyectable que incluye trabectedina para uso gastrointestinal externo y metodo para la fabricacion de la misma.
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
WO2020239478A1 (en) 2019-05-28 2020-12-03 Pharma Mar, S.A. Trabectedin for treating sarcomas based on genomic markers
CN112574234B (zh) * 2019-09-27 2022-05-24 江苏恒瑞医药股份有限公司 一种海鞘素衍生物的制备方法
EP4041194B1 (de) 2020-04-15 2024-03-13 EVER Valinject GmbH Zusammensetzung mit trabectedin und einer aminosäure
US20230226051A1 (en) 2022-01-20 2023-07-20 Extrovis Ag Trabectedin composition

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5149804A (en) * 1990-11-30 1992-09-22 The Board Of Trustees Of The University Of Illinois Ecteinascidins 736 and 722
WO1987007610A2 (en) * 1986-06-09 1987-12-17 University Of Illinois Ecteinascidins 729, 743, 745, 759a, 759b and 770
US5089273A (en) 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
US5256663A (en) * 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
DE3635711A1 (de) 1986-10-21 1988-04-28 Knoll Ag 5-nitrobenzo(de)isochinolin-1,3-dione, ihre herstellung und verwendung
GB8805268D0 (en) * 1988-03-04 1988-04-07 Glaxo Group Ltd Medicaments
GB9101221D0 (en) * 1991-01-19 1991-02-27 Smithkline Beecham Plc Pharmaceuticals
US5721352A (en) 1991-02-19 1998-02-24 University Of Florida Research Foundation Entomopoxvirus expression system
FR2697752B1 (fr) 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US5891704A (en) * 1992-11-19 1999-04-06 Anticancer, Inc. Method to produce high levels of methioninase
JPH09503743A (ja) * 1993-05-14 1997-04-15 デポテック コーポレーション 神経学的疾患の治療方法
US5478932A (en) 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
US20040059112A1 (en) 1994-02-18 2004-03-25 Rinehart Kenneth L. Ecteinascidins
US5919816A (en) * 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
GB9508195D0 (en) 1995-04-20 1995-06-07 Univ British Columbia Novel biologically active compounds and compositions,their use and derivation
US5721362A (en) * 1996-09-18 1998-02-24 President And Fellows Of Harvard College Process for producing ecteinascidin compounds
DE69738935D1 (de) * 1996-11-05 2008-10-02 Childrens Medical Center Zusammensetzungen enthaltend Thalidomide und Dexamethason für die Behandlung von Krebs
IL123740A0 (en) * 1997-03-28 1998-10-30 Pfizer NK-1 receptor antagonists for the treatment of delayed emesis
US5985876A (en) * 1997-04-15 1999-11-16 Univ Illinois Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
DE19720312A1 (de) * 1997-05-15 1998-11-19 Hoechst Ag Zubereitung mit erhöhter in vivo Verträglichkeit
GB9801231D0 (en) * 1997-06-05 1998-03-18 Merck & Co Inc A method of treating cancer
BR9909488B1 (pt) * 1998-04-06 2011-02-08 ecteinascidinas semi-sintéticas e composição farmacêutica.
EP1077698B1 (de) * 1998-05-11 2005-03-02 Pharma Mar, S.A. Ecteinascidinderivate
US6124292A (en) 1998-09-30 2000-09-26 President And Fellows Of Harvard College Synthetic analogs of ecteinascidin-743
MY164077A (en) 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
MY130271A (en) 1999-05-14 2007-06-29 Pharma Mar Sa Hemisynthetic method and new compounds
CA2406080C (en) 2000-04-12 2011-11-29 Pharma Mar, S.A. Antitumoral ecteinascidin derivatives
US7247892B2 (en) 2000-04-24 2007-07-24 Taylor Geoff W Imaging array utilizing thyristor-based pixel elements
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
US7420051B2 (en) 2000-05-15 2008-09-02 Pharma Mar, S.A. Synthetic process for the manufacture of an ecteinaschidin compound
JP2004506430A (ja) 2000-08-11 2004-03-04 シティ・オブ・ホープ Ｓｘｒによるトランス活性化の抗新生物剤ｅｔ−７４３による阻害
CA2428160C (en) 2000-11-06 2009-10-13 Pharma Mar, S.A. Compositions for antitumor treatment containing ecteinascidin 743
EP1360337A1 (de) 2001-02-09 2003-11-12 The Regents Of The University Of California Mitglieder der ecteinascidin familie: zusammensetzungen und methoden
EP1372658A2 (de) 2001-03-30 2004-01-02 Shire Biochem Inc. Verfahren zur behandlung von krebs, wobei cyplastin kombiniert mit einem dioxalan nukleosid wie troxacitabin verwendet wird
GB0121285D0 (en) 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
HUP0401903A3 (en) 2001-10-19 2008-07-28 Pharma Mar Improved use of et-743 in cancer thereapy
US20040019027A1 (en) 2002-04-12 2004-01-29 Barry Forman Method of treating cerebrotendinous xanthomatosis
GB0312407D0 (en) 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
GB0324201D0 (en) 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
RS50692B (sr) 2003-11-13 2010-06-30 Pharma Mar S.A.U. Kombinacija et-743 sa prolekovima 5-fluorouracila za lečenje kancera
GB0326486D0 (en) 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
AU2004291037A1 (en) 2003-11-14 2005-06-02 Pharma Mar, S.A. Combination therapy comprising the use of ET-743 and paclitaxel for treating cancer
MX2007000360A (es) 2004-07-09 2007-06-12 Pharma Mar Sa Marcadores moleculares de pronostico.
US20080242670A2 (en) 2004-09-29 2008-10-02 Pharma Mar S.A., Sociedad Unipersonal Anti-Inflammatory Agents
NZ554765A (en) 2004-10-26 2010-01-29 Pharma Mar Sa Pegylated Liposomal Doxorubicin In Combination With Ecteinescidin 743
DE602005001833T2 (de) 2004-10-29 2008-04-17 Pharma Mar S.A., Sociedad Unipersonal Zusammensetzungen enthaltend Ecteinascidin und einen Disaccharide
DE602006020335D1 (de) 2005-11-25 2011-04-07 Pharma Mar Sa Verwendung von parp-1-hemmern
JP2009536956A (ja) 2006-05-12 2009-10-22 ファルマ・マール・ソシエダード・アノニマ 抗癌治療法

Also Published As

Publication number Publication date
PT1716853E (pt) 2011-05-12
UA74782C2 (uk) 2006-02-15
DE60036826D1 (de) 2007-11-29
SI1176964T1 (sl) 2007-02-28
PT1176964E (pt) 2007-01-31
CZ20014081A3 (cs) 2002-11-13
HUS1500001I1 (hu) 2016-08-29
CZ301482B6 (cs) 2010-03-17
CA2373794C (en) 2005-10-11
SK287580B6 (sk) 2011-03-04
PT1702618E (pt) 2008-01-11
IL146434A (en) 2008-03-20
SI1716853T1 (sl) 2011-10-28
AU777417B2 (en) 2004-10-14
FR08C0013I2 (fr) 2009-10-30
DE60030554T2 (de) 2007-09-13
BG65680B1 (bg) 2009-06-30
NL300337I1 (nl) 2008-05-01
NL300337I2 (nl) 2008-09-01
JP2002544231A (ja) 2002-12-24
AR028476A1 (es) 2003-05-14
NO324564B1 (no) 2007-11-19
JP5777562B2 (ja) 2015-09-09
CA2373794A1 (en) 2000-11-23
BR0010531A (pt) 2002-06-04
EP1176964B1 (de) 2006-09-06
US8119638B2 (en) 2012-02-21
PL352931A1 (en) 2003-09-22
LU91418I2 (fr) 2008-05-13
AU4597500A (en) 2000-12-05
US20070275942A1 (en) 2007-11-29
FR08C0013I1 (de) 2008-05-30
CN1679631A (zh) 2005-10-12
SK16442001A3 (sk) 2002-03-05
EP1716853B1 (de) 2011-03-09
MY164077A (en) 2017-11-30
CN100477993C (zh) 2009-04-15
EP1716853B9 (de) 2011-09-28
SI1702618T1 (sl) 2008-02-29
EP1702618A3 (de) 2006-12-27
PL198185B1 (pl) 2008-06-30
EP1716853A3 (de) 2006-11-15
WO2000069441A1 (en) 2000-11-23
BG106171A (en) 2002-06-28
CY1112753T1 (el) 2016-02-10
NO20015516L (no) 2002-01-11
CY2008007I1 (el) 2009-11-04
AU2005200180B2 (en) 2007-12-13
ATE375795T1 (de) 2007-11-15
CN1360503A (zh) 2002-07-24
DE60030554T8 (de) 2008-01-10
MXPA01011562A (es) 2002-07-30
AU2005200180A1 (en) 2005-02-10
DE60030554D1 (de) 2006-10-19
DK1702618T3 (da) 2008-02-25
ES2272279T3 (es) 2007-05-01
CY1105818T1 (el) 2011-02-02
EP1176964B8 (de) 2007-10-10
HUP0201187A2 (en) 2002-09-28
NO2008005I1 (no) 2008-06-09
EP1176964A1 (de) 2002-02-06
HU229866B1 (en) 2014-10-28
EP1702618B1 (de) 2007-10-17
DK1716853T3 (da) 2011-06-27
EP1716853A2 (de) 2006-11-02
NO20015516D0 (no) 2001-11-12
JP2012149095A (ja) 2012-08-09
LU91418I9 (de) 2019-01-02
NO2008005I2 (de) 2010-09-27
AU2005200180B9 (en) 2008-05-29
HUP0201187A3 (en) 2002-11-28
ES2294756T3 (es) 2008-04-01
ATE338552T1 (de) 2006-09-15
DK1176964T3 (da) 2007-01-15
ATE500830T1 (de) 2011-03-15
DE122008000013I1 (de) 2008-08-07
NZ515423A (en) 2004-04-30
CY1107143T1 (el) 2010-07-28
IL146434A0 (en) 2002-07-25
CY2008007I2 (el) 2009-11-04
TR200103819T2 (tr) 2002-04-22
KR20020019914A (ko) 2002-03-13
DE60036826T2 (de) 2008-08-28
EP1702618A2 (de) 2006-09-20

Similar Documents

Publication Publication Date Title
DE60045720D1 (de) Behandlung von Krebs beim Menschen mit ET743
ATE363904T1 (de) Benzimidazol-2-carbamat zur behandlung viraler infektionen und von krebs
DE60222671D1 (de) Thienopyrimidinedione und deren verwendung in der behandlung von autoimmunerkrankungen
BR9508886A (pt) Compostos e métodos para o tratamento de câncer
DE60023128D1 (de) Pyrazolecarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen
NO993396L (no) Kinolin- og kinolinforbindelser nyttige i terapi, spesielt i behandlingen av benign prostatisk hyperplasi
TR199501053A2 (tr) Tedavide yararli spiro-azabisiklik bilesikler.
PT1083889E (pt) Compostos de tetra-hidronaftaleno e sua utilizacao no tratamento de doencas neurodegenerativas
DE69836008D1 (de) Zusammensetzung und behandlungsmittel
IS5504A (is) Samsetning virk við meðhöndlun á getuleysi
NO992069D0 (no) Konjugater som kan anvendes ved behandling av prostatakreft
DE60012138D1 (de) Gerät zur behandlung von fibrillation
DE60023454D1 (de) Lagenmaterialen mit tensid-modifizierten chelatbildern behandelt
NO20020358L (no) Anvendelse av etodolac til behandling av kreft
NO20002189D0 (no) Anvendelse av makrolider for behandling av cancer og mukuladegenerasjon
DE60027429D1 (de) Dihydrobenzodiazepinen und deren verwendung zur behandlung von dyslipidämien
BR9612283A (pt) Composição para o tratamento de manchas em peças de roupa e métodos de tratamento
NO20002804D0 (no) Konjugater som kan anvendes ved behandling av prostatakreft
PT984777E (pt) Piperazinas arilsubstituidas uteis no tratamento da hiperplasia benigna da prostata
PT932400E (pt) Derivados de anticonvulsionantes uteis no tratamento da dor neuropatica
DE69828228D1 (de) Zitrusfruchtessig und Herstellungsverfahren
NO20014228L (no) Radioaktiv cisplatin i behandling av cancer
EE200300057A (et) Koostis vähi profülaktikaks ja raviks
FI980543A0 (fi) Spetsdragningsanordning och foerfarande foer spetsdragning av en bana
DE69737570D1 (de) Agentien zur präsymptomatischen Detektion, Prävention und Behandlung von Brustkrebs in Menschen